Metformin reshaped glioblastoma immunity and improved radiotherapy response in mice
Metformin plus radiotherapy prolonged survival in two syngeneic glioblastoma models while shifting macrophage and T-cell populations toward antitumor phenotypes.
Tag
glioblastoma
Most glioblastoma recurrences clustered within 10 mm of the original GTV
In 201 recurrent glioblastomas, 80% required no more than 10.4 mm expansion to encompass 80% of recurrence volume.
Cannabinoids reduced glioblastoma apoptosis after chemotherapy and radiation in vitro
Several cannabinoids reduced therapy-induced glioblastoma apoptosis and enhanced clonogenic survival in vitro, raising concern about concurrent use during treatment.
Six-fraction chemoradiation worsened survival in newly diagnosed glioblastoma
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
Modelled actinium-225 delivery reduced glioblastoma clonogens but had limited spatial reach
Convection-enhanced actinium-225 markedly reduced modelled clonogenic survival, but effective coverage extended only about 1.4 cm from each catheter.
Glioblastoma brachytherapy remains limited by non-standardized dosimetry
Modern intracavitary platforms can intensify pericavitary dose immediately after surgery, but standardized patient-specific dosimetry and comparative clinical evidence remain lacking.
Bragg peak proton FLASH matched CyberKnife plans and cut beam delivery to seconds
In 10 recurrent glioblastoma replans, Bragg peak proton FLASH improved conformity and reduced estimated beam delivery from approximately 17 minutes to under two seconds.
IGF1R blockade overcame oHSV and radiotherapy resistance in glioblastoma and breast cancer models
Triple oHSV, radiotherapy and IGF1R blockade suppressed YAP1, produced tumour regressions and prolonged survival in glioblastoma and breast cancer models.
Higher-dose iodine-125 brachytherapy was associated with longer survival in recurrent glioblastoma
Iodine-125 doses of 140–160 grays were associated with longer median survival than 120–140 grays in recurrent glioblastoma.
Tumor treating field arrays increased surface dose during photon radiotherapy
Tumor treating field arrays caused substantial surface dose enhancement and measurable dose attenuation during 6-megavolt photon irradiation.
Hypofractionated proton reirradiation showed similar survival to photons in recurrent glioblastoma
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.